Oasis Donor Site Wounds Post-Market Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Oasis ECM: The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
standard wound care: The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of standard wound care to their donor site wound.
Study summary
The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom. Oasis ECM is commercially available for the treatment of partial and full-thickness skin wounds, including chronic wounds, wounds from trauma, and wounds that occur during surgery, such as donor site wounds. The ability of the Oasis ECM to promote the healing of donor site wounds will be evaluated in this study.
About 40 patients (20 in each arm) over 16 years old will be involved in this study at one center in the United Kingdom.
Eligibility
Primary outcome measure(s)
- Donor site wound healing — 14 days
To demonstrate the percentage of patients with wounds healed at day 14
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Manchester University NHS Foundation Trust | Manchester | England | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04079348 on ClinicalTrials.gov ↗ ← All trials in the UK